



Contact:

Dr. Misha Plam, President & CEO

(303) 641-3669

misha.plam@amidebio.com

www.amidebio.com

AmideBio Announces Availability of BioPure™ Amyloid-beta for Alzheimer's Research

BOULDER, CO, June 20, 2013 – AmideBio LLC, an early stage biotech R&D company, announces the commercial availability of BioPure™ Amyloid-beta 1-42 (A β 42) peptide for scientific research on the pathology of Alzheimer's disease. The peptide may now be purchased in laboratory research quantities from AmideBio with purity, reproducible quality, and reliability never before achieved. The (A β 42) peptide is believed to play a central, but not yet completely understood role in the pathology of Alzheimer's disease.

AmideBio's BioPure™ process provides >99% pure peptide from a proprietary method combining recombinant protein expression and chemical methods to produce proteins and peptides with previously unattainable purity and cost efficiency. Traditional production methods contain impurities that can severely compromise the quality and reproducibility of experimental results. The BioPure™ process yields unprecedented peptide purity with a cost-effectiveness that can significantly boost the research community's efforts to tackle Alzheimer's. AmideBio has begun supplying qualified researchers with test samples free of charge as an introductory promotion.

AmideBio's President & CEO Dr. Misha Plam commented, "After a rigorous development effort, we are pleased to introduce best in class Amyloid-beta to the research community. Amyloid-beta is the first in a series of products we plan to introduce using our proprietary technology to supply laboratory researchers with the quality of material that they expect and deserve. AmideBio is committed to providing the highest quality peptide products for neuroscience research and discovery, including such programs as the BRAIN Initiative recently announced by President Obama".

About AmideBio:

AmideBio, based in Boulder, CO, is an early-stage biotechnology company that has developed a unique technology for producing peptides and proteins, especially ones that previously were difficult to manufacture in large quantities. The Company is expanding its proprietary technology platform to address protein production, biosimilar therapeutic manufacturing, and internal research and development of novel targets for biotherapeutics to treat inflammatory and neurodegenerative diseases. AmideBio's BioPure™ process provides the research community with the purest peptide-derived products available to date, including Amyloid-beta, a protein believed to be a key player in Alzheimer's disease.

-ENDS-